Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.61 USD | +0.36% | -11.95% | -26.11% |
Financials (USD)
Sales 2024 * | 126M | Sales 2025 * | 181M | Capitalization | 2.8B |
---|---|---|---|---|---|
Net income 2024 * | -313M | Net income 2025 * | -300M | EV / Sales 2024 * | 18.9 x |
Net cash position 2024 * | 426M | Net cash position 2025 * | 313M | EV / Sales 2025 * | 13.8 x |
P/E ratio 2024 * |
-8.23
x | P/E ratio 2025 * |
-8.9
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.51% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | +0.36% | ||
1 week | -11.95% | ||
Current month | -20.94% | ||
1 month | -19.65% | ||
3 months | -31.82% | ||
6 months | -13.01% | ||
Current year | -26.11% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 22.61 | +0.36% | 1,300,210 |
24-04-17 | 22.53 | -4.82% | 1,149,585 |
24-04-16 | 23.67 | -1.42% | 796,315 |
24-04-15 | 24.01 | -2.79% | 878,553 |
24-04-12 | 24.7 | -3.82% | 856,153 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.11% | 2.79B | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- ARWR Stock